Skip to main content

BRIEF RESEARCH REPORT article

Front. Oncol.
Sec. Genitourinary Oncology
Volume 14 - 2024 | doi: 10.3389/fonc.2024.1400041

External validation of hemoglobin and neutrophil levels as predictors of the effectiveness of ipilimumab plus nivolumab for treating renal cell carcinoma

Provisionally accepted
Shuzo Hamamoto Shuzo Hamamoto 1*Yoshihiko Tasaki Yoshihiko Tasaki 1Shimpei Yamashita Shimpei Yamashita 2Junya Furukawa Junya Furukawa 3Kazutoshi Fujita Kazutoshi Fujita 4Ryotaro Tomida Ryotaro Tomida 5Miyake Makito Miyake Makito 6Noriyuki Ito Noriyuki Ito 7Hideto Iwamoto Hideto Iwamoto 8Yosuke Sugiyama Yosuke Sugiyama 1Kazumi Taguchi Kazumi Taguchi 1Takahiro Yasui Takahiro Yasui 1
  • 1 Nagoya City University, Nagoya, Japan
  • 2 Wakayama Medical University, Wakayama, Wakayama, Japan
  • 3 Kobe University, Kobe, Hyōgo, Japan
  • 4 Kindai University, Higashi-osaka, Ōsaka, Japan
  • 5 Tokushima University, Tokushima, Tokushima, Japan
  • 6 Nara Medical University, Kashihara, Nara, Japan
  • 7 Japanese Red Cross Society Wakayama Medical Center, Wakayama, Wakayama, Japan
  • 8 Tottori University, Tottori, Tottori, Japan

The final, formatted version of the article will be published soon.

    Introduction: Pretreatment hemoglobin and neutrophil levels were previously reported to be important indicators for predicting the effectiveness of ipilimumab plus nivolumab (IPI + NIVO) therapy for renal cell carcinoma (RCC). Therefore, we aimed to validate this in a large external cohort. Methods: In total, 172 patients with RCC who underwent IPI + NIVO treatment at a multicenter setting were divided into three groups according to their pretreatment hemoglobin and neutrophil levels (group 1: non-anemia, group 2: anemia and low-neutrophil, and group 3: anemia and high-neutrophil). Results: Group 1 showed better survival than groups 2 and 3 (overall survival: 52.3 vs. 21.4 vs. 9.4 months, respectively; progression-free survival: 12.1 vs. 7.0 vs. 3.4 months, respectively). Discussion: In this large cohort, we validated our earlier observation that hemoglobin and neutrophil levels can be reliable predictors of the effectiveness of IPI + NIVO in advanced RCC. Thus, our approach may aid in selecting the optimal first-line therapy for RCC.

    Keywords: Hemoglobin, Neutrophil, ipilimumab plus nivolumab, Renal cell carcinoma, External validation

    Received: 12 Mar 2024; Accepted: 08 Aug 2024.

    Copyright: © 2024 Hamamoto, Tasaki, Yamashita, Furukawa, Fujita, Tomida, Makito, Ito, Iwamoto, Sugiyama, Taguchi and Yasui. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

    * Correspondence: Shuzo Hamamoto, Nagoya City University, Nagoya, Japan

    Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.